Noble Capital initiated coverage of YS Biopharma with an Outperform rating and $5.25 price target. The company’s novel PIKA technology has the capability to target and accelerate the immune response in a wide variety of vaccines and immuno-oncology therapeutics and the firm sees “significant opportunities” in anti-viral and immuno-oncology markets, citing large unmet needs in Africa, Southeast Asia and China in rabies, hepatitis B and cancers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on YS:
- YS Biopharma completion enrollment in Phase 3 clinical trial of rabies vaccine
- YS Biopharma receives Nasdaq noncompliance notice
- YS Biopharma enrolls first subject in Phase 3 clinical trial of rabies vaccine
- YS Biopharma granted new patent covering PIKA YS-HBV-002
Questions or Comments about the article? Write to editor@tipranks.com